Osiris Therapeutics, Inc. News Releases http://investor.osiris.com/ Osiris Therapeutics, Inc. News Releases en Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc http://investor.osiris.com/news-releases/news-release-details/osiris-therapeutics-inc-announces-closing-acquisition-smith COLUMBIA, Md. , April 17, 2019 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that it has completed the previously announced sale of Osiris Wed, 17 Apr 2019 09:05:00 -0400 Osiris Therapeutics, Inc. News Releases 12616 Smith & Nephew expands in high growth regenerative medicine market through acquisition of Osiris Therapeutics, Inc. http://investor.osiris.com/news-releases/news-release-details/smith-nephew-expands-high-growth-regenerative-medicine-market LONDON , March 12, 2019 /PRNewswire/ --  Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, announces that it has agreed to acquire Osiris Therapeutics, Inc. (NASDAQ: OSIR), a fast growing company delivering regenerative medicine products, including skin, bone graft and Tue, 12 Mar 2019 09:33:00 -0400 Osiris Therapeutics, Inc. News Releases 12521 Osiris Therapeutics, Inc. Enters Agreement to be Acquired by Smith & Nephew plc http://investor.osiris.com/news-releases/news-release-details/osiris-therapeutics-inc-enters-agreement-be-acquired-smith COLUMBIA, Md. , March 12, 2019 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, today announced that it has entered into an agreement and plan of merger with Tue, 12 Mar 2019 09:00:00 -0400 Osiris Therapeutics, Inc. News Releases 12506 Osiris Therapeutics, Inc. Appoints Samson Tom, PhD, MBA to Serve as President and Chief Executive Officer http://investor.osiris.com/news-releases/news-release-details/osiris-therapeutics-inc-appoints-samson-tom-phd-mba-serve COLUMBIA, Md. , Nov. 26, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, is pleased to announce that its Board of Directors appointed Samson Tom , PhD, Mon, 26 Nov 2018 16:30:00 -0500 Osiris Therapeutics, Inc. News Releases 12491 Osiris Therapeutics, Inc Reports Third Quarter 2018 Results http://investor.osiris.com/news-releases/news-release-details/osiris-therapeutics-inc-reports-third-quarter-2018-results COLUMBIA, Md. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, today reported its results for the third quarter ending September 30, 2018 . Wed, 07 Nov 2018 16:15:00 -0500 Osiris Therapeutics, Inc. News Releases 12461 Osiris Therapeutics, Inc. to Present Advanced Clinical and Scientific Abstracts at Symposium on Advanced Wound Care (SAWC) Fall Meeting, November 2-4, 2018, in Las Vegas, Nevada http://investor.osiris.com/news-releases/news-release-details/osiris-therapeutics-inc-present-advanced-clinical-and-scientific COLUMBIA, Md. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, will present advanced clinical and scientific research at the Symposium on Tue, 30 Oct 2018 16:30:00 -0400 Osiris Therapeutics, Inc. News Releases 12456 Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Demonstrating That Lyopreservation Method Developed for Living Tissues is an Alternative to Cryopreservation with the Convenience of Ambient Storage http://investor.osiris.com/news-releases/news-release-details/osiris-therapeutics-inc-announces-peer-reviewed-publication-0 COLUMBIA, Md. , Oct. 02, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that a new peer-reviewed manuscript entitled “Properties of Tue, 02 Oct 2018 16:30:00 -0400 Osiris Therapeutics, Inc. News Releases 12451 Osiris Therapeutics, Inc. Announces GrafixPL PRIME™ Launches October 1, 2018 http://investor.osiris.com/news-releases/news-release-details/osiris-therapeutics-inc-announces-grafixpl-primetm-launches COLUMBIA, Md. , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announces that GrafixPL PRIME™, a human placental membrane that can be stored Mon, 17 Sep 2018 17:00:00 -0400 Osiris Therapeutics, Inc. News Releases 12441 Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Comparing the Efficacy of Viable Cryopreserved Placental Membranes to Human Fibroblast-Derived Dermal Substitute in the Treatment of Chronic Diabetic Foot Ulcers (DFUs) in a Multicenter Randomi http://investor.osiris.com/news-releases/news-release-details/osiris-therapeutics-inc-announces-peer-reviewed-publication COLUMBIA, Md. , Aug. 27, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc.  (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that a new peer-reviewed manuscript entitled “A multicenter, Mon, 27 Aug 2018 16:30:00 -0400 Osiris Therapeutics, Inc. News Releases 12416 Osiris Therapeutics, Inc. to Re-list on The Nasdaq Global Market on August 1, 2018 http://investor.osiris.com/news-releases/news-release-details/osiris-therapeutics-inc-re-list-nasdaq-global-market-august-1 COLUMBIA, Md. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, today announced that The Nasdaq Stock Market LLC has approved its application to Wed, 01 Aug 2018 08:00:00 -0400 Osiris Therapeutics, Inc. News Releases 12406